CAMP4 Therapeutics Corp. (CAMP), a clinical-stage biotechnology company that went public in 2024, anticipates 2025 to be a crucial year, with a key clinical trial catalyst expected in the second half of the year.
The company is pioneering a new class of RNA medicines to increase targeted gene expression, with the potential to provide meaningful clinical benefits for prevalent diseases where gene upregulation is likely to be effective. Its lead drug candidate is CMP-CPS-001, being developed for the treatment of Urea Cycle Disorders.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com